Annual balance sheet for Boundless Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 73 | 66.7 | 121 | 152 | 108 |
| Prepaid Expenses | |||||
| Total Current Assets | 74.6 | 68 | 124 | 154 | 110 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.1 | 7.73 | 4.58 | 51.4 | 46.9 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 114 | 76.8 | 130 | 206 | 157 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.87 | 7.73 | 9.36 | 8.13 | 12.5 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.96 | 10.6 | 9.36 | 55.8 | 58.4 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 110 | 66.3 | 121 | 151 | 98.7 |
| Total Liabilities & Shareholders' Equity | 114 | 76.8 | 130 | 206 | 157 |
| Total Common Shares Outstanding |